ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 01 Oct 2018
Last Updated on 01 Oct 2018
A- A+
Guidance Recommendation
The Ministry of Health's Drug Advisory Committee has recommended:
  • Solifenacin 5 mg tablet for treating overactive bladder.

Subsidy status

Solifenacin 5 mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL).


Solifenacin for OAB (1 Oct 2018)